Children born to mothers who took metformin may face an increased risk of obesity, finds a new study. The findings of this study are published in the Journal of Clinical Endocrinology and Metabolism.
A growing number of pregnant women are taking metformin to treat gestational diabetes or a condition called polycystic ovary syndrome (PCOS). PCOS is a common cause of infertility and can put women at risk of developing diabetes and other metabolic health problems. PCOS affects an estimated 7 percent to 10 percent of women of childbearing age, according to the Hormone Health Network.
‘Children born to women who took metformin drug for polycystic ovary syndrome and gestational diabetes during pregnancy are more likely to meet the criteria for obesity than children whose mothers that were not taking the drug during pregnancy.’
When pregnant women with PCOS or gestational diabetes take metformin, the medication crosses the placenta and is passed to the fetus.
"Our findings indicate the offspring of women who took metformin for PCOS during pregnancy are more likely to meet the criteria for obesity or overweight than children whose mothers were given a placebo during pregnancy," said the study's first author, Liv Guro Engen Hanem, M.D., of the Norwegian University of Science and Technology in Trondheim, Norway. "The results were surprising since limited past research in this area had suggested metformin would have a protective effect on the children's metabolic health."
The researchers invited parents of 292 children who participated in two previous randomized clinical trials to be part of this study. In the previous trials, pregnant women with PCOS were assigned to take either metformin or placebo during pregnancy. The researchers wound up reviewing body mass index (BMI) and other measurements for 161 children born following the two earlier studies.
At four years of age, the children whose mothers were randomized to metformin during pregnancy tended to weigh more than the children whose mothers took the placebo. Although metformin did not appear to affect birth weight, the trend became apparent when children reached six months of age. At the age of four years, the children in the metformin group had higher BMI scores and were more likely to meet the criteria for obesity or overweight than children in the placebo group.
"Few studies have examined the long-term health of children born to women with PCOS who took metformin," Hanem said. "Our findings indicate more research is needed to determine its effects on children who were exposed in the womb."
Other authors of the study include: Solhild Stridsklev, Sven M. Carlsen, Rřnnaug Řdegĺrd and Eszter Vanky of the Norwegian University of Science and Technology and St. Olavs Hospital, Trondheim University Hospital, both in Trondheim, Norway; Pétur B. Júlíusson of the University of Bergen in Bergen, Norway; and Mathieu Roelants of KU Leuven - University of Leuven in Belgium.